{
  "docId": "019de074-4969-72b8-bf99-262b9202adeb",
  "docSlug": "32d16c961ba3228c7796678a3b67d91c",
  "documentTitle": "ATAI | Investor Presentation Deck | 33 slides",
  "authorId": "atai",
  "authorName": "atai Life Sciences",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-02-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 29,
  "pageCount": 33,
  "prevPage": 28,
  "nextPage": 30,
  "slideType": "executive_summary",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 12,
  "notes": "The slide uses a split-layout: a left-hand sidebar for company/product facts and a right-hand main area for clinical data and trial design.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-4969-72b8-bf99-262b9202adeb/29",
  "deckHref": "/decks/019de074-4969-72b8-bf99-262b9202adeb",
  "deckJsonHref": "/decks/019de074-4969-72b8-bf99-262b9202adeb.json",
  "deckAnchorHref": "/decks/019de074-4969-72b8-bf99-262b9202adeb#slide-29",
  "components": [
    {
      "bbox": {
        "h": 0.28,
        "w": 0.58,
        "x": 0.37,
        "y": 0.28
      },
      "kind": "chart",
      "text": "Prior evidence in humans (third party study) showing HCQN subscale reduction over time",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7d5f0d77-30de-4926-9936-9654e4f4686b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.22,
        "w": 0.58,
        "x": 0.37,
        "y": 0.68
      },
      "kind": "diagram",
      "text": "Ongoing Phase 1/2 trial structure: Stage 1 (Max Tolerated Dose) and Stage 2 (Proof of Concept)",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d0a1489b-6bee-4cf9-97e9-1771ecf3230c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.6,
        "x": 0.37,
        "y": 0.91
      },
      "kind": "disclaimer",
      "text": "Note: HCQN = Heroin Craving Questionnaire, PK = Pharmacokinetics. 1. Ownership percentage... 2. Mash et al., 'Ibogaine Detoxification...'",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e791f66d-32c6-4cd5-a6bc-727da7c4f529",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.75,
        "w": 0.33,
        "x": 0.03,
        "y": 0.15
      },
      "kind": "table",
      "text": "Ownership: 59.5%, Product: DMX-1002, Pharmacology: Receptor modulator, Features: Rapid withdrawal, Indications: OUD/PTSD/TBI, Status: Phase 1/2, IP: Pending claims, Highlight: Sustained reduction",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "293479dc-162c-42da-8769-b28ae07f324f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.6,
        "x": 0.37,
        "y": 0.07
      },
      "kind": "title",
      "text": "A single-dose of ibogaine showed potential for sustained reductions in opioid cravings in 75 opioid-dependent patients",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a1cf7064-3254-4c8f-bcbd-d15dce68331b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.13,
        "x": 0.03,
        "y": 0.07
      },
      "kind": "title",
      "text": "SUMMARY",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "eac87db3-5a43-411a-bf4b-8e78ea3d227c",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Executive summary",
      "slug": "executive-summary",
      "agent": null,
      "layer": "slide",
      "matchId": "3babbeb7-6df0-407b-b922-0eee0caa4de4",
      "evidence": "table/data: Ownership: 59.5%, Product: DMX-1002, Pharmacology: Receptor modulator, Features: Rapid withdrawal, Indications: OUD/PTSD/TBI, Status: Phase 1/2, IP: Pending claims, Highlight: Sustained reduction",
      "confidence": 0.7
    }
  ],
  "frameworks": [
    {
      "name": "executive-summary",
      "slug": null,
      "matchId": "7e86220d-7140-43a1-9bde-e915b929da1a",
      "evidence": "Structured as a high-level summary of company and clinical data.",
      "confidence": 1
    }
  ],
  "arcBeats": [],
  "loops": [
    {
      "to": 33,
      "from": 3,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "720e63ac-a674-4bf4-8e46-acf9a0a900ae",
      "evidence": "The presentation follows the Golden Circle framework, starting with why atai Life Sciences is working on mental health disorders (p3) and presenting their solution and traction.",
      "position": 1,
      "objective": "Why is atai Life Sciences' solution important?",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.7,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}